Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Factor Xa or thrombin: is thrombin a better target?

J I Weitz1

  • 1Henderson Research Centre and McMaster University, Hamilton, ON, Canada. jweitz@thrombosis.hhscr.org

Journal of Thrombosis and Haemostasis : JTH
|August 1, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Relationship between Surgery and Trauma and Risk of Recurrence in Patients with an Associated First Venous Thrombotic Event: A Nested Case-Control Study.

Thrombosis and haemostasis·2025
Same author

Corrigendum to "Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: Results from the Hokusai VTE Cancer study" [Thromb. Res. vol. 185, January 2020, pages 13-19].

Thrombosis research·2020
Same author

Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: Results from the Hokusai VTE Cancer study.

Thrombosis research·2019
Same author

Fibrinolysis: strategies to enhance the treatment of acute ischemic stroke.

Journal of thrombosis and haemostasis : JTH·2018
Same author

Addressing the burden of hospital-related venous thromboembolism: the role of extended anticoagulant prophylaxis.

Journal of thrombosis and haemostasis : JTH·2018
Same author

Rivaroxaban reversal with prothrombin complex concentrate or tranexamic acid in healthy volunteers.

Journal of thrombosis and haemostasis : JTH·2017

New oral anticoagulants targeting thrombin or factor Xa offer alternatives to vitamin K antagonists. Thrombin inhibitors show promise, with newer agents like dabigatran etexilate emerging after earlier ones were withdrawn.

Area of Science:

  • Pharmacology
  • Biochemistry
  • Hematology

Background:

  • Vitamin K antagonists have limitations, driving the development of novel oral anticoagulants targeting specific coagulation enzymes.
  • Current research focuses on agents inhibiting thrombin or factor Xa, key players in the coagulation cascade.

Discussion:

  • Thrombin, as the final effector of coagulation and a potent platelet agonist, represents a logical target for anticoagulant therapy.
  • Clinical trials indicate that reversible direct thrombin inhibitors offer a wider therapeutic window compared to irreversible ones.
  • The success of oral direct thrombin inhibitors like dabigatran etexilate validates thrombin as a viable therapeutic target, despite earlier challenges with agents like ximelagatran due to hepatotoxicity.

Key Insights:

  • Reversible direct thrombin inhibitors demonstrate clinical efficacy and a favorable safety profile, supporting thrombin as a prime target.

Related Experiment Videos

  • The development of oral anticoagulants has shifted towards targeted enzyme inhibition, moving beyond traditional vitamin K antagonists.
  • While ximelagatran faced market withdrawal, newer agents like dabigatran etexilate are successfully filling the therapeutic gap.

    • Outlook:

    • Ongoing clinical trials are evaluating oral factor Xa inhibitors, presenting a comparative analysis with thrombin inhibitors.
    • The comparative efficacy and safety of targeting thrombin versus factor Xa will determine future anticoagulant strategies.
    • Further research is needed to definitively establish whether thrombin or factor Xa is the superior target for next-generation oral anticoagulants.